911069-05-1

Upstream product

• 71449-08-6 (2R)-2-{[(benzyloxy)carbonyl]amino}-4-tert-butoxy-4-oxobutanoic acid 
• 127852-30-6 (R)-α-(m-(trifluoromethyl)phenyl)ethylamine 
• 911069-02-8 N-[(benzyloxy)carbonyl]-D-aspartic acid β-tert-butyl ester α-{[(R)-1-(trifluoromethyl)phenyl]ethyl}amide 

Downstream Products

• 911068-20-7 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-[1-(3-trifluoromethyl-phenyl)-ethyl]-succinamic acid tert-butyl ester 
• 911068-29-6 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-[1-(3-trifluoromethyl-phenyl)-ethyl]-succinamic acid 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treati

METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER

Compounds and compositions are described herein for treating post tramatic stress disorder.

BETA-LACTAM CANNABINOID RECEPTOR MODULATORS

Described herein are substituted 2-(azetidin-2-on-l-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CBl) and/or canna

β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

β-lactamyl alkanoic acids and pharmaceutical compositions thereof are described. Methods for treating various diseases and disease states using one or more β-lactamyl alkanoic acids are also described. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids,

Azetidinones as vasopressin V1a antagonists

The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing h

BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS

0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more β-lactamyl alkanoic acids are also described.